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Multiple myeloma (MM) is a B-cell malignancy charac-
terized by proliferation of monoclonal plasma cells in
the bone marrow. Bone disease is detected at diagnosis
by conventional radiographs of the skeleton in 80% of
the patients and may cause bone pain, pathological
fractures, and hypercalcemia (1). Most patients respond
to initial treatment, but eventually almost all patients
will have resistant relapse and die from the disease. In
the last decade, many new agents have been introduced
for treatment of MM. These novel agents have a strik-
ing effect on the disease, and it is now often possible
to bring a patient into remission multiple times during
the course of the disease (2–4). Thus, the life of a
patient with MM is now commonly characterized by
multiple remissions and relapses. Continuous monitor-
ing of early signs of end organ damage is important to
enable timely intervention before serious damage has
occurred.
Abstract
Objective: Monitoring of bone disease in multiple myeloma is becoming increasingly important because
bone-protecting treatment with bisphosphonate is becoming restricted after the awareness of osteonecro-
sis of the jaw. Despite the potential of biochemical markers of bone remodeling to monitor dynamic bone
turnover, they are not used in everyday practice. Here, we investigate their usefulness to detect imminent
progressive osteolysis in relapsing patients with multiple myeloma. Methods: In an unselected cohort of
93 patients, we measured the bone resorption markers C-terminal telopeptide of collagen type I (CTX-I),
C-terminal cross-linked telopeptide of type-I collagen generated by MMPs (ICTP), N-terminal cross-linked
telopeptide of type-I collagen (NTX-I), and the bone formation marker bone-speciﬁc alkaline phosphatase
(bALP) monthly for 2 yr. Retrospectively, we identiﬁed 40 cases where patients had progressive disease.
We investigated how the bone markers developed prior to disease progression. Results: We observed that
CTX-I and bALP changed signiﬁcantly before progressive disease were recognized. More interestingly,
these changes differed depending on whether concurrent progressive osteolysis was present. In patients
with progressive osteolysis, there was a large increase in bone resorption which was not compensated
by increased bone formation. In contrasts, patients with stable bone disease had only a slight increase
in bone resorption which was compensated by concurrent increased bone formation. By calculating
a patient-speciﬁc CTX-I⁄bALP ratio, we quantiﬁed the risk a patient experiences if the ratio increases.
Conclusion: By analyzing patient-speciﬁc changes in the ratio of CTX-I⁄bALP, we might tailor treatment
with bone-protecting agents in the individual patient.
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MM is that the myeloma cells produce several factors
that stimulate osteoclast (OC) formation and activity
(5–9) and inhibit osteoblast (OB) function and bone
formation (10–13). Treatment with bisphosphonate inhib-
its OC activity and reduce the number of new skeletal
events in MM (14), and bisphosphonates are integrated
into standard management of patients with MM. How-
ever, prolonged exposure to potent bisphosphonates may
cause kidney damage (15) and osteonecrosis of the jaw
(ONJ) (16). This has led to a more cautious and restricted
use of bisphosphonates, and most international guidelines
now recommend that treatment is limited to a 2-yr period
for patients in remission (17, 18). However, patients in
remission are still at risk of developing new osteolytic
lesions. A recent guideline for monitoring patients with
MM recommends that radiographs, CT-scans, or MR
scans are taken only when clinically indicated after the
initial staging of the patient (19). With this strategy, sub-
stantial damage may have occurred in bone before the
patient becomes symptomatic and progressive bone dis-
ease is detected. Biochemical markers of bone turnover
may represent an interesting alternative to evaluate the
bone status of patients with myeloma. They are not
harmful and are compatible with monthly monitoring.
They have the potential to detect the destructive process
as soon as it starts and before a lesion becomes detectable
through conventional radiography. Thus, markers should
allow therapeutic intervention as soon as the problem
starts. Several of these markers have been used in clinical
trials in patients with MM. The trials included markers of
bone resorption as well as markers of bone formation
because lesions reﬂect not only bone destruction but also
impaired bone reconstruction. These bone remodeling
markers have shown good correlation to histomorpho-
metric changes (20, 21), have yielded prognostic informa-
tion in newly diagnosed patients (22–29), and shown
signiﬁcant changes in response to treatment (30–34).
Despite their potential interest, markers of bone
remodeling are not used in everyday practice, and their
usefulness to detect progressive osteolysis in relapsing
patients has not even been investigated. This gap appears
especially important at the present time as the typical
patient with MM undergoes relapses and remissions mul-
tiple times, and because it is unknown how long the
patient remains protected after the discontinuation of
bisphosphonate treatment.
The aim of this study was to test if some of the most
promising bone markers, the bone resorption markers
CTX-I, ICTP, and NTX-I and the bone formation marker
bALP could yield clinically useful information in a general
myeloma population and help with decision making in
daily clinical practice. More speciﬁcally, we wanted to test
whether the bone remodeling markers could, at a patient-
speciﬁc level, provide an early warning of progressive dis-
ease and⁄or development of new osteolytic lesions before
symptoms occur. If so, markers of bone turnover could
potentially be used to tailor bisphosphonate and other rel-
evant therapies in the individual patient. This strategy
could in some patients reveal the need of reinstating anti-
resorptive or anti-myeloma treatment and could in other
patients reduce exposure to unnecessary bisphosphonate,
thereby minimizing the risk of long-term side effects.
Materials and methods
Patients
An unselected cohort of patients with multiple myeloma
followed at Vejle Hospital, Denmark, had the bone deg-
radation markers CTX-I, ICTP, NTX-I and the bone for-
mation marker bALP measured every 4 wk for 2 yr.
Measurements were conducted on 93 patients (49 men⁄44
women). The median age of the patients was 69 yr (range:
44–90 yr), and bone markers were measured at 1233 dif-
ferent time points. The study was approved by the Danish
Data Protection Agency and conducted according to the
national ethical guidelines and the Helsinki Declaration.
Markers of bone remodeling were measured every
fourth wk. The disease status of the patients was moni-
tored using serum M-component (IgG or IgA), serum-
free light kappa⁄lambda chains (FLC), and ionized
serum calcium at least every fourth wk. Progressive dis-
ease (PD) was deﬁned as a 25% or greater increase in
serum M-component or in patients with light-chain mye-
loma an increase in the difference between involved and
uninvolved FLC (>100 mg⁄L), or deﬁnite development
of one or more new bone lesions, according to the Inter-
national Uniform Response Criteria for Multiple Mye-
loma (35). In cases with PD, the patients own bone
marker values at the time point when disease activity was
lowest prior to the relapse, deﬁned by nadir of M-compo-
nent or FLC ratio, were compared to the patient-speciﬁc
values observed when PD was detected. The median time
from the lowest disease activity as reﬂected by the nadir
of M-component or FLC to PD was 5 months. Radio-
graphs were performed in patients with bone symptoms
and in some cases with increasing values of M-compo-
nent or FLC at the discretion of the treating physician.
During the study period, twenty-nine patients pre-
sented with either biochemical and⁄or radiological evi-
dence of progressive disease after having been in
remission. Ten patients experienced two episodes of dis-
ease progression and one patient three episodes, giving a
total of 40 episodes of PD for evaluation in this study.
For these 40 cases, a retrospective analysis was
performed in the prospectively collected and analyzed
bone markers to see whether patient-speciﬁc changes in
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demographics and clinical parameters for patients with
PD are shown in Table 1.
Of the 40 cases of progressive disease that was
observed in the study period, we identiﬁed 26 cases
where radiological evaluation was conducted at the time
of PD. Fifteen patient had concomitant progressive oste-
olysis, whereas no progression was detectable in 11 cases.
Patient-speciﬁc development in the bone markers prior
to PD was analyzed for the two groups to identify
distinct patterns for the two groups.
In 17 patients who received novel anti-myeloma treat-
ment, no data were available concerning the preceding
period of disease progression, either because it was ﬁrst-
line treatment in newly diagnosed patients or because
disease progression occurred before measurement of
bone remodeling markers was initiated. Of the remaining
47 patients in the cohort, 15 patients had a limited num-
ber bone marker measure points, 10 patients were on
continuous anti-myeloma treatment, 2 patients had smol-
dering myeloma only, and 5 patients were either lost to
follow-up because of transfer to other hospital or were
not evaluable as they were not fasting or nadir values
were missing. Fifteen patients had stable disease in the
observation period, but only in ﬁve of these patients, sta-
ble bone disease were veriﬁed as bone imaging did not
reveal any progression in osteolysis.
Measurements of bone degradation and bone forma-
tion markers
Blood samples were collected in the morning from fasting
patients. The samples were immediately centrifuged and
the serum was stored for a maximum period of 1 month
prior to analysis. Urine samples were collected as fasting
second void morning urine and stored in the same way.
Prior to analysis, the urine was centrifuged. Samples for
bALP, NTX-I, and ICTP analysis were stored at )80 C.
Samples for CTX-I analysis were stored at )20 C (36).
Serum CTX-I was measured by an enzyme chemilumines-
cence method (Roche Diagnostic, Hvidovre, Denmark).
Competitive enzyme immunoassays were used to measure
serum ICTP (Orion Diagnostica, Espoo, Finland) and
urine NTX-I (Ostex International, Seattle, WA, USA),
respectively. Serum bALP was measured with a non-com-
petitive enzyme immunoassay technique (Quidel Corpora-
tion, San Diego, CA, USA). ICTP, NTX-I, and BAP
were analyzed in duplicates. The lower detection limits
were CTX-I: 0.01 lg⁄L, NTX-I: 20 nmol⁄L, ICTP:
1 lg⁄L, and bALP: 0.7 units⁄L. Urine NTX-I was
normalized and expressed relative to urine creatinine.
Evaluation of bone disease
Development of bone disease was evaluated by skeletal
survey using either conventional radiography or com-
puter tomography (CT-scan). Skeletal survey was
conducted according to ‘Guidelines for the use of imag-
ing in the management of myeloma’ (19). All images
were interpreted by a senior radiologist. Only skeletal
surveys done within 1 month after ﬁrst sign of PD were
used for further analysis (Table 1).
Statistical analysis
Patient-speciﬁc differences in CTX-I, BAP, CTX-I⁄bALP
ratio, ICTP, and creatinine were analyzed using a paired
t-test. The tests were adjusted for clustering to compen-
sate for the fact that some patients contributed with
more than one dataset. NTX-I⁄creatinine was analyzed
both using a Wilcoxon matched pair test and a paired
t-test adjusted for clustering. Differences in progression
of bone disease were analyzed using both an unpaired
t-test adjusted for clustering and the Cox regression
model. All P-values are two-sided and the signiﬁcance
level was set at P £ 0.05.
Results
Bone markers and disease progression
The bone resorption marker CTX-I showed a signiﬁcant
44% increase when its level in a patient at ﬁrst sign of
Table 1 Patient characteristics for patients with progressive disease
(PD)
Number of cases⁄patients 40⁄29
Sex (male⁄female) 20⁄20
Age* (years) 66.5(55–90)
Time from SD to PD* (months) 5(2–16)
M-component type
IgG 26
IgA 5
Light chain only 9
Bisphosphonate status
Naive 3
Previously treated 14
Currently treated 23
Relapse no
1st 15
2nd 10
3rd or higher 15
Relapse deﬁned by
Increase in paraprotein only 25
Progression in bone disease only 5
Both 10
Progression in bone disease
Yes 15
No 11
Unknown 14
*Age and time from SD to PD are shown as median values with
ranges.
Bone markers can detect imminent osteolysis Lund et al.
414 ª 2010 John Wiley & Sons A/SPD was compared with its level in the same patient at
nadir of the M-component or FLC (Fig. 1). The average
increase in CTX-I became statistical signiﬁcant 1 month
prior to the detection of PD and subsequently increased
further with time (Fig. 2), prior to that no consistent
changes were observed (data not shown). Even though
bALP levels were very low, with a mean level of
14.15 Units⁄L (normal range 15–41 Units⁄L), a signiﬁ-
cant 17 % increase was observed at ﬁrst sign of PD
(Fig. 1). bALP levels remained low during the entire per-
iod, and although the average increase became statistical
signiﬁcant 2 months prior to the detection of PD by con-
ventional markers, values started to decline again before
PD was reached (Fig. 2). No signiﬁcant changes were
observed in the bone degradation markers NTX-I or
ICTP (Fig. 1). The increase in CTX-I and bALP could
not be ascribed to deteriorating kidney function as serum
creatinine remained stable in the observed period (data
not shown).
Correlation of markers of bone turnover with
radiological evidence of progressive osteolysis
CTX-I increased signiﬁcantly both in patients with or
without concomitant progression in bone disease. An
increase of 0.11 lg⁄L was observed in patients with pro-
gressive osteolysis, whereas a signiﬁcant smaller increase
of 0.03 lg⁄L was observed in patients with no detectable
progression in osteolysis. All patients with an observed
CTX-I increase of more than 0.12 lg⁄L, regardless of
Figure 1 Comparison of levels of bone remodeling markers at stable disease and at ﬁrst sign of progressive disease. (A) The bone resorption
marker CTX-I showed a small, however, highly signiﬁcant increase in patients having progressive disease. (B) Although drastically suppressed, the
bone formation marker bALP increased signiﬁcantly at disease progression. (C–D) Both resorption markers NTX-I and ICTP remained unchanged.
Results are shown as mean ± SEM of 37 (C) and 40 (A–B, D) cases. ***P < 0.001; **P < 0.01 using a paired t-test adjusted for clustering.
Figure 2 Changes in serum levels of CTX-I and bALP prior to progressive disease (PD). (A) CTX-I progressively increased reaching signiﬁcance
1 month prior to ﬁrst sign of progressive disease. (B) bALP reaches signiﬁcance 2 months prior to PD, the increase reached a maximum 1 month
prior to ﬁrst sign of progressive disease. Results are shown as mean ± SEM of 40 cases (A–B). ***P < 0.001; **P < 0.01; *P < 0.05 comparing
all values to value at stable disease (SD) using a paired t-test adjusted for clustering.
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The bone formation marker bALP remained highly sup-
pressed in patients with progressive osteolysis, whereas a
small increase was observed in patients with stable bone
disease compensating for the small CTX-I increase. Fur-
thermore, all cases where bALP decreased more that
3 units⁄L presented with progressive osteolysis (Fig. 3B)
The different patterns of change of CTX-I and bALP
levels in patients with and without radiological evidence
of bone disease probably reﬂects increased uncoupling of
bone remodeling in patients with progressive osteolysis.
A CTX-I⁄bALP ratio was calculated for each patient to
estimate the degree of uncoupling. At time of PD, the
mean patient-speciﬁc ratio increased 8.7 ng⁄unit in
patients with radiologically detected progression of bone
disease. In contrast, the ratio was unchanged if no new
bone lesions could be visualized. In case of a decreasing
ratio, it was unlikely that a patient suffered from pro-
gressive osteolysis as it was only observed in 1 of 6 cases;
sensitivity 93%. Contrasting this, ratios that increased
more than 5.2 ng⁄units were a good indication of pro-
gressive osteolysis as this was observed in 9 of 10 cases;
speciﬁcity 0.91% (Fig. 3C). Observing the ratio from SD
and onward, there was a tendency for decreased values
in the group with no detectable progression in bone dis-
ease, whereas the ratio on average increased signiﬁcantly
already 2 months after SD and remained positive in
patients who later developed new osteolytic lesions
(Fig. 3D). If ‘failure’ is deﬁned as progression of bone
disease, Cox regression analysis of the CTX-I⁄bALP
ratio resulted in a hazard ratio of 1.077 (P < 0.05).
Surprisingly, two patients with radiologically detected
progression of bone disease had decreased values of
CTX-I. However, they also had decreased values of
bALP which resulted in an increased CTX-I⁄bALP ratio
in accordance with their progression of bone disease.
Discussion
The average life expectancy of patients with MM has
increased in recent years after introduction of several
novel agents for treatment of patients with MM (37).
During recent years, evidence has emerged suggesting
that long-term treatment with potent bisphosphonates
may cause ONJ. This has led to a more restrictive use of
bisphosphonates. With prolonged survival of patients
Figure 3 Changes in CTX-I and bALP in the individual patients stratiﬁed according to progression in osteolytic lesions. (A) Patient-speciﬁc CTX-I
increased signiﬁcantly in patients with progressive osteolysis, a much smaller although still signiﬁcant increase was observed in patients with sta-
ble bone disease. The seven patients with the highest change in CTX-I all had progression in osteolysis. (B) bALP did not show a compensatory
increase to CTX-I in patients with progressive osteolysis. The ﬁve patients with the greatest decline all had deteriorating bone status. In patients
with stable bone disease, a small signiﬁcant increase was observed in bALP thereby compensating for the likewise small increase in CTX-I. (C)
The CTX-I⁄bALP ratio increased signiﬁcantly in the patients with contemporary bone disease compared to patients with stable bone disease. Nine
of ten patients with an increase over 5.2 had progressive osteolysis, whereas ﬁve of six patients with decreasing values had stable bone disease.
(D) Development in the CTX-I⁄bALP ratio evaluated from stable disease and onward. Analysis was conducted until fewer than ﬁve datasets
remained for evaluation. Patients with progressive osteolysis (PO) showed signiﬁcantly increased values from the second month after stable dis-
ease. Patients with stable bone disease had a tendency to decreasing values although insigniﬁcant. Results are shown as patient-speciﬁc changes
in bone markers as a mean of 11 and 15 cases, respectively (A–C). ***P < 0.001; **P < 0.01; *P < 0.05 using either an unpaired (A–C) or a
paired (D) t-test adjusted for clustering.
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will get to a point where the potential beneﬁts and disad-
vantages of continued bisphosphonate treatment should
be considered. Continued treatment will increase the risk
of ONJ, whereas discontinued treatment will increase the
risk of osteolysis and fractures. So far, there are no clini-
cal data to guide us on an individual basis, neither about
the optimal duration of initial bisphosphonate treatment
nor on the risks and beneﬁts of reinstituted bisphospho-
nate treatment at the time of progression. Recent guide-
lines recommend that radiographs should not be taken
routinely, but only at tangible suspicion or symptoms of
progression of osteolytic bone disease. However, with
this approach, substantial and irreversible bone damage
may occur before treatment with bone-protecting agents
is initiated.
Several biochemical markers have been suggested in
the past to be of value for evaluation of osteolytic bone
disease in MM. However, they have only been tested
either at diagnosis and used as prognostic markers or
after initiation of new therapy. Our data are unique
because they describe what happens before disease pro-
gression with or without progressive osteolysis occurs.
This could only be done because we measured bone
markers monthly in a large group of patients during a
long period. Furthermore, previous studies have been
conducted in strictly deﬁned patient populations. The
reason for this is probably that factors such as bis-
phosphonate treatment, disease stage, and to a lesser
extent anti-myeloma treatment have a major impact on
bone marker levels. We did likewise observations in our
study, making analyses on absolute values obscure in this
heterogeneous population. However, if we took into
account patient-speciﬁc changes regardless of absolute
values, we were able to identify a unique pattern. We dis-
covered that patient-speciﬁc changes in CTX-I, bALP,
and the ratio of CTX-I⁄bALP could distinguish between
relapse with or without concomitant progression of bone
disease and that changes in the CTX-I⁄bALP ratio
increases in cases with new osteolytic lesions and other-
wise remain unchanged. The Cox regression model
reported an increased relative risk of progressive osteoly-
sis to be 7.7% if the ratio increased with 1. In some
patients, we observed that the ratio increased with up to
30.
It is noteworthy that skeletal surveys and⁄or CT scans
were only performed in 26 of 40 cases. Skeletal imaging
was not done routinely but only at suspicion of bone dis-
ease according to international guidelines. Moreover, it
can be expected that some patients deﬁned as having sta-
ble bone disease were miscategorized because of lack of
sensitivity of the conventional radiography. If our ﬁnd-
ings are conﬁrmed in a prospective setting where bone
status is evaluated routinely in all patients using more
sensitive methods e.g. CT scans, it can be expected that
the group of patients without progression would be more
homogeneous. Such a study will probably result in an
even stronger separation of the CTX-I⁄bALP ratio when
comparing patients with or without progressive bone dis-
ease.
That CTX-I and NTX-I may be used to monitor bone
disease is a reasonable assumption. Collagen type I con-
stitutes 90% of the organic bone matrix (38), and CTX-I
and NTX-I are the most abundantly released products
from collagen degradation (39). Furthermore, both
markers are known to decline in patients responding to
anti-myeloma treatment (32–34, 40, 41). Because of bis-
phosphonate treatment, both the values of CTX-I and
NTX-I were suppressed. The CTX-I values, however,
remained within detection range, whereas many NTX-I
values were below the lower detection limit both at stable
and progressive disease. It was probably because of this,
we were unable to detect any increase in NTX-I. Thus,
CTX-I seems to be a more robust marker for osteolytic
activity than NTX-I in patients treated with bisphospho-
nates because of the CTX-I assays ability to detect
changes even at low absolute levels.
ICTP is generated by other proteolytic enzymes com-
pared to CTX-I and NTX-I (42) and has been shown to
be of prognostic value in all ISS subgroups (27). In the
present study, we found very high ICTP levels. ICTP,
however, remained continuously elevated regardless of
disease progression. Our ﬁndings are contradicted by two
small studies that showed increasing ICTP values in
patients with progressive disease (23, 43). However, both
studies were carried out in bisphosphonate naı¨ve
patients. In conclusion, although ICTP is highly elevated
in MM and yields valuable prognostic information when
used at diagnosis, it appears less informative when used
for continuous monitoring.
Bone disease in MM is not only because of an
increased bone resorption but also caused by inhibition
of bone formation. As expected, our patients had highly
depressed bALP levels (mean 14.15; normal range 15–
41). Even so, we were still able to detect an increase in
the patients with stable bone disease compensating for
an increase in CTX-I. The fact that osteoblast activity
may increase to compensate for increased bone resorp-
tion in a well described phenomenon in early stage mye-
loma (44–46). Furthermore, it is interesting that no
increase in bALP was observed in patients with progres-
sive osteolysis. The importance of evaluating changes in
both OC and OB function is highlighted by the fact that
no patients in our study had progression in bone disease
without showing either increasing CTX-I values or
decreasing bALP values. Two patients with progression
in bone disease had decreasing levels of both CTX-I and
bALP. Thus, their progression was more likely caused by
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drugs targeting OB inhibitors are currently being investi-
gated. Hypothetically, bone markers may help us to deter-
mine whether a patient will beneﬁt most from treatment
with bisphosphonates or e.g. antibodies against DKK-1.
In conclusion, we detected speciﬁc changes in bone
markers prior to disease progression and progressive
osteolysis. This was rendered possible because we did not
look at absolute levels but at changes in the individual
patient. The changes were consistent even in a very het-
erogeneous population. This gives our ﬁndings a high
external validity, making it usable in everyday clinical
life. Measurements of CTX-I and bALP, and the calcu-
lated CTX-I⁄bALP ratio, could become very important
tools for monitoring myeloma bone disease and possibly
guide the initiation of treatment with bisphosphonates or
newer bone-protecting drugs before extensive bone
destruction occurs (31, 41). However, prospective studies
with preplanned bone imaging are needed to validate our
ﬁndings and deﬁne relevant individual changes in the
bone remodeling markers. Furthermore, randomized
studies must prove if patient tailored treatment reduces
progressive osteolysis.
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